BACKGROUND: The availability of genotype-specific therapy for PML/RAR alpha(pos) acute promyelocytic leukemia (APL) requires that this disease be precisely diagnosed. Immunophenotypic characteristics heretofore proclaimed as reliably characterizing APL (HLA-DR(low), CD34(low), P-glycoprotein(low) myeloid phenotype) do not differentiate from APL-like immune profiles unassociated with the PML/RAR alpha fusion transcript. METHODS: To establish a surrogate marker profile for APL, we explored 19 potentially predictive markers compared with differentiated acute myeloid leukemia using the classification tree approach with recursive partitioning. RESULTS: In a test group of 58 APL patients, the most predictive immune profile was HLA-DR(low), CD11a(low) (alpha(L) subunit of the leukocyte integrin LFA-1), CD18(low) (beta(2) subunit of LFA-1). APL cells always expressed CD117 (c-kit) but lacked the progenitor antigen CD133 and the more mature myeloid antigen, CD11b (alpha(M) leukocyte integrin). This antigen pattern was validated in 90 additional APL patients. M3v APLs (n = 30) had more leukemic promyelocytes expressing the T-cell antigen, CD2 (P < 0.0001) or the stem cell marker, CD34 (P = 0.0003) and demonstrated higher fluorescence intensity for the binding of antibody to the common leukocyte antigen, CD45 (P = 0.0008) than M3 (n = 102). S-form APL (n = 45) had a higher percent of cells expressing CD2 or CD34 (P < 0.0001 for both) or the neural cell adhesion molecule CD56 (P = 0.001) than L-form APL (n = 66). CONCLUSIONS: PML/RAR alpha(pos) APL cells typically lack leukocyte integrins. HLA-DR(low), CD11a(low), CD18(low) is a reliable surrogate antigen expression profile for PML/RAR alpha(pos) APL, irrespective of morphology and transcript isoform. Copyright 2004 Wiley-Liss, Inc.
BACKGROUND: The availability of genotype-specific therapy for PML/RAR alpha(pos) acute promyelocytic leukemia (APL) requires that this disease be precisely diagnosed. Immunophenotypic characteristics heretofore proclaimed as reliably characterizing APL (HLA-DR(low), CD34(low), P-glycoprotein(low) myeloid phenotype) do not differentiate from APL-like immune profiles unassociated with the PML/RAR alpha fusion transcript. METHODS: To establish a surrogate marker profile for APL, we explored 19 potentially predictive markers compared with differentiated acute myeloid leukemia using the classification tree approach with recursive partitioning. RESULTS: In a test group of 58 APL patients, the most predictive immune profile was HLA-DR(low), CD11a(low) (alpha(L) subunit of the leukocyte integrin LFA-1), CD18(low) (beta(2) subunit of LFA-1). APL cells always expressed CD117 (c-kit) but lacked the progenitor antigen CD133 and the more mature myeloid antigen, CD11b (alpha(M) leukocyte integrin). This antigen pattern was validated in 90 additional APL patients. M3v APLs (n = 30) had more leukemic promyelocytes expressing the T-cell antigen, CD2 (P < 0.0001) or the stem cell marker, CD34 (P = 0.0003) and demonstrated higher fluorescence intensity for the binding of antibody to the common leukocyte antigen, CD45 (P = 0.0008) than M3 (n = 102). S-form APL (n = 45) had a higher percent of cells expressing CD2 or CD34 (P < 0.0001 for both) or the neural cell adhesion molecule CD56 (P = 0.001) than L-form APL (n = 66). CONCLUSIONS:PML/RAR alpha(pos) APL cells typically lack leukocyte integrins. HLA-DR(low), CD11a(low), CD18(low) is a reliable surrogate antigen expression profile for PML/RAR alpha(pos) APL, irrespective of morphology and transcript isoform. Copyright 2004 Wiley-Liss, Inc.
Authors: Laura M Pardo; Andrew P Voigt; Todd A Alonzo; Elisabeth R Wilson; Robert B Gerbing; Dana J Paine; Fangyan Dai; Andrew J Menssen; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Soheil Meshinchi; Denise A Wells; Lisa Eidenschink Brodersen; Michael R Loken Journal: Cytometry B Clin Cytom Date: 2019-07-11 Impact factor: 3.058
Authors: Eva Barragán; Pau Montesinos; Mireia Camos; Marcos González; Maria J Calasanz; José Román-Gómez; Maria T Gómez-Casares; Rosa Ayala; Javier López; Óscar Fuster; Dolors Colomer; Carmen Chillón; María J Larrayoz; Pedro Sánchez-Godoy; José González-Campos; Félix Manso; Maria L Amador; Edo Vellenga; Bob Lowenberg; Miguel A Sanz Journal: Haematologica Date: 2011-06-17 Impact factor: 9.941
Authors: Marvin M van Luijn; Theresia M Westers; Martine E D Chamuleau; S Marieke van Ham; Gert J Ossenkoppele; Arjan A van de Loosdrecht Journal: Am J Pathol Date: 2011-09-09 Impact factor: 4.307
Authors: Martin S Tallman; Haesook T Kim; Pau Montesinos; Frederick R Appelbaum; Javier de la Serna; John M Bennett; Guillermo Deben; Clara D Bloomfield; Jose Gonzalez; James H Feusner; Marcos Gonzalez; Robert Gallagher; Jose D Gonzalez-San Miguel; Richard A Larson; Gustavo Milone; Elisabeth Paietta; Chelo Rayon; Jacob M Rowe; Concha Rivas; Charles A Schiffer; Edo Vellenga; Lois Shepherd; James L Slack; Peter H Wiernik; Cheryl L Willman; Miguel A Sanz Journal: Blood Date: 2010-09-21 Impact factor: 22.113
Authors: Adi Diab; Lynette Zickl; Omar Abdel-Wahab; Suresh Jhanwar; Manjit A Gulam; Katherine S Panageas; Jay P Patel; Joseph Jurcic; Peter Maslak; Elisabeth Paietta; James K Mangan; Martin Carroll; Hugo F Fernandez; Julie Teruya-Feldstein; Selina M Luger; Dan Douer; Mark R Litzow; Hillard M Lazarus; Jacob M Rowe; Ross L Levine; Martin S Tallman Journal: Leuk Res Date: 2012-10-24 Impact factor: 3.156